Claims for Patent: 11,857,543

Summary for Patent: 11,857,543

Title:	Compositions and methods for treating anemia
Abstract:	Provided herein are specific doses of, and dosing regimens for, using a HIF prolyl hydroxylase inhibitor in treating or preventing anemia, such as anemia secondary to or associated with chronic kidney disease, anemia associated with or resulting from chemotherapy, or anemia associated with AIDS.
Inventor(s):	Robert Shalwitz, Charlotte Hartman, Akshay Buch, Isaiah Shalwitz, John Janusz, Joseph Gardner
Assignee:	Akebia Therapeutics Inc
Application Number:	US14/897,849
Patent Claims:	1. A method for treating anemia secondary to or associated with chronic kidney disease, comprising orally administering to a patient having said anemia an effective amount of a compound which is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure, or a pharmaceutically acceptable salt thereof, wherein a daily dose comprises 150±30 mg, 300±30 mg, 450±30 mg, 600±30 mg, or 750±30 mg of the compound. 2. The method of claim 1, wherein the compound is a pharmaceutically acceptable salt of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid. 3. The method of claim 1, wherein the compound is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid. 4. The method of claim 1, wherein the chronic kidney disease is stage 3, 4, or 5 chronic kidney disease. 5. The method of claim 1, wherein the chronic kidney disease is pre-dialysis chronic kidney disease. 6. The method of claim 1, wherein the daily dose is administered orally, once daily. 7. The method of claim 1, wherein the patient has not been previously treated for anemia. 8. The method of claim 1, where the patient is refractory to treatment with recombinant erythropoietin. 9. The method of claim 1, wherein the patient has been previously treated for anemia. 10. The method of claim 1, wherein hemoglobin levels of the patient a. are maintained at a level of at least about 9.0 g/dL and at or below about 13.0 g/dL; or b. are maintained at a level of at least about 10.0 g/dL and at or below about 13.0 g/dL; or c. are maintained at a level of at least about 11.0 g/dL and at or below about 13.0 g/dL; or d. are increased by at least about 1.2 g/dL relative to a baseline hemoglobin level. 11. The method of claim 10 wherein the hemoglobin levels are tested at least about 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, or about 8 weeks after the initial administering of the compound. 12. The method of claim 1, wherein the compound is administered in combination with another medicament. 13. The method of claim 12, wherein the other medicament is an iron supplement. 14. The method of claim 13, wherein the iron supplement is administered at least two hours following administration of the compound. 15. The method of claim 13, wherein the iron supplement is administered in an amount such that ferritin is maintained at a level of between about 50 ng/mL and about 300 ng/mL. 16. The method of claim 13, wherein the iron supplement is administered orally at a daily dose about 50 mg of elemental iron. 17. The method of claim 13, wherein the iron supplement is administered (i) on an as needed basis; (ii) continuously; and/or (iii) indefinitely. 18. The method of claim 1, wherein the compound is administered once a day every day during treatment at the same time of the day. 19. The method of claim 18, wherein the time of day is in the morning or 2 pm. 20. The method of claim 1, further comprising taking a first measurement of the hemoglobin level in the patient and subsequently taking a second measurement of the hemoglobin level in the patient, wherein i. if the hemoglobin level in the patient at the second measurement is less than about 10.0 g/dL and the level of hemoglobin has increased by less than about 0.5 g/dL as compared to the level at the first measurement; or ii. if the hemoglobin level in the patient at the second measurement is less than about 10.0 g/dL and the level of hemoglobin has changed by up to about 0.4 g/dL as compared to the level at the first measurement; or iii. if the hemoglobin level in the patient at the second measurement is between about 10.0 and about 10.9 g/dL and the level of hemoglobin has decreased by less than about 0.5 g/dL as compared to the level at the first measurement; then administering an adjusted daily dose of the compound that is greater than the initial daily dose. 21. The method of claim 1, further comprising taking a first measurement of the hemoglobin level in the patient and subsequently taking a second measurement of the hemoglobin level in the patient, wherein i. if the hemoglobin level in the patient at the second measurement is less than about 10.0 g/dL and the level of hemoglobin has increased by greater than about 1.5 g/dL as compared to the level at the first measurement; or ii. if the hemoglobin level in the patient at the second measurement is between about 10.0 and about 10.9 g/dL and the level of hemoglobin has increased by greater than about 1.5 g/dL as compared to the level at the first measurement; or iii. if the hemoglobin level in the patient at the second measurement is between about 11.0 and about 12.2 g/dL and the level of hemoglobin has increased by between about 1.0 and about 1.4 g/dL as compared to the level at the first measurement; or iv. if the hemoglobin level in the patient at the second measurement is between about 12.3 and about 12.9 g/dL and the level of hemoglobin has decreased by up to about 0.4 g/dL or increased by up to about 0.4 g/dL as compared to the at the first measurement; or v. if the hemoglobin level in the patient at the second measurement is between about 12.3 and about 12.9 g/dL and the level of hemoglobin has increased by about 0.5 to about 0.9 g/dL as compared to the level at the first measurement; then administering an adjusted daily dose of the compound that is less than the initial daily dose. 22. The method of claim 1, further comprising taking a first measurement of the hemoglobin level in the patient and subsequently taking a second measurement of the hemoglobin level in the patient, wherein i. if the hemoglobin level in the patient at the second measurement is between about 11.0 and about 12.2 g/dL and the level of hemoglobin has increased by greater than about 1.5 g/dL as compared to the level at the first measurement; or ii. if the hemoglobin level in the patient at the second measurement is between about 12.3 and about 12.9 g/dL and the level of hemoglobin has increased by between about 1.0 and about 1.4 g/dL as compared to the level at the first measurement; or iii. if the hemoglobin level in the patient at the second measurement is between about 12.3 and about 12.9 g/dL and the level of hemoglobin has increased by greater than between about 1.5 g/dL as compared to the level at the first measurement; then administering an adjusted daily dose of the compound that is less than the initial daily dose. 23. The method of claim 1, wherein the patient has predialysis chronic kidney disease. 24. The method of claim 1, wherein the patient is a dialysis patient. 25. The method of claim 1, wherein the daily dose is administered as two tablets, each comprising 150 mg of the compound. 26. The method of claim 20, wherein the adjusted daily dose of the compound is about 150 mg greater than the initial daily dose. 27. The method of claim 20, wherein the adjusted daily dose of the compound is 600 mg. 28. The method of claim 21, wherein the adjusted daily dose of the compound is about 150 mg less than the initial daily dose. 29. The method of claim 22, wherein the adjusted daily dose of the compound is about 150 mg less than the initial daily dose. 30. The method of claim 1, wherein a daily dose comprises 300±30 mg of the compound.